Antibody-mediated Rejection, Lung Transplant Rejection
Conditions
Brief summary
Antibody mediated rejection (AMR) post transplant contributes to poor long term outcomes after lung transplantation. Additionally, high antibodies detected pre transplant in candidates limit donor availability for lung transplant. This proposal would include belatacept in a multi-therapy regimen. Open label study with two patient cohorts for safety and efficacy of belatacept in a multi-modal protocol. The two patient cohorts are an AMR post-transplant cohort and pre-transplant desensitization cohort. A total of 10 patients will be enrolled.The primary objection is drug tolerability and secondary objectives are antibody measurements and allograft function.
Detailed description
Antibody mediated rejection (AMR) post transplant contributes to poor long term outcomes after lung transplantation. Additionally, high antibodies detected pre transplant in candidates limit donor availability for lung transplant. Multimodal therapies with rituximab, intravenous immunoglobulin, plasmapheresis and proteasome inhibitors have not significantly altered the antibodies in these patients. Belatacept targets the T and B cell interaction such that it represents a novel therapeutic strategy. This proposal would include belatacept in a multi-therapy regimen. This is an open label study with two patient cohorts for safety and efficacy of belatacept in a multi-modal protocol. The two patient cohorts are an AMR post-transplant cohort and pre-transplant desensitization cohort. A total of 10 patients will be enrolled.The primary objection is drug tolerability and secondary objectives are antibody measurements and allograft function.
Interventions
DRUGBelatacept
Initial phase: 10 mg/kg on days 0 and 4, and again at weeks 2 and 4. Maintenance phase: 10 mg/kg every month beginning 4 weeks after completion of the initial phase. No dosage adjustments required for renal or hepatic impairment. No known drug interactions for usual post-transplant medication regimen.
DRUGCarfilzomib
20mg/m2 Plasmapheresis
Sponsors
Bristol-Myers Squibb
Duke University
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Inclusion criteria for the AMR post-transplant cohort * Positive DSAs and allograft dysfunction defined by changes in pulmonary physiology, gas exchange, radiological features or deteriorating functional performance that is highly suspicious for AMR * Recipient is Epstein-Barr virus positive (EBV+) by serology * Ability to provide signed and dated IRB approved written consent in accordance with regulatory and institutional guidelines prior to any protocol-related procedure Inclusion criteria for the pre-transplant desensitization cohort * Elevated HLA antibodies (defined as MFI \>1000) such that the calculated panel reactive antibodies are \>60% * At least 2 HLA antibodies with Mean Fluorescent Intensity (MFI) \<10,000 and at least 2 HLA antibodies with MFI \<5,000 on undiluted serum that do not demonstrate an increase in MFI with dilution at 1:16 (no evidence of a prozone effect). * EBV+ by serology * Clinically stable defined by not on invasive mechanical ventilation, extracorporeal membrane oxygenation support or other invasive life support requiring ICU level of care * Ability to provide signed and dated IRB approved written consent in accordance with regulatory and institutional guidelines prior to any protocol-related procedure
Exclusion criteria
for both AMR post-transplant cohort and pre-transplant cohort * Active systemic infection * Allergy to carfilzomib or belatacept * Known malignancy in the previous 2 years except for non-melanomatous skin cancer * Pregnancy * Inability to commit to complete treatment protocol at Duke as all procedures must be completed at Duke * Prisoners or those who are compulsory detained
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Occurrence of drug side effects | Within 28 days of last administration of study drugs | Drug tolerability with respect to freedom from drug side effects measured using descriptive statistics |
| Occurrence of infection | Within 28 days of last administration of study drugs | Drug tolerability with respect to freedom from infection measured using descriptive statistics |
| Occurrence of malignancy | Within 28 days of last administration of study drugs | Drug tolerability with respect to freedom from malignancy measured using descriptive statistics |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of subjects in the AMR cohort with decrease in DSA by one log | Within 4 weeks of completion of treatment | Descriptive statistical report of number of subjects who had a decrease in DSA measured by absolute Mean Fluorescent Intensity (MFI) change and log change using pre and post treatment values for each antibody. |
| Number of subjects in the AMR cohort with elimination of DSA at 1:16 dilution | Within 4 weeks of completion of treatment | Descriptive statistical report of number of subjects who had elimination of DSA at 1:16 dilution measured by absolute Mean Fluorescent Intensity (MFI) change and log change using pre and post treatment values for each antibody. |
| Number of subjects in the AMR cohort with resolution of at least one donor specific human leukocyte antigen (HLA) antibody (DSA) | Within 4 weeks of completion of treatment | Descriptive statistical report of number of subjects who had resolution of at least one DSA measured by absolute Mean Fluorescent Intensity (MFI) change and log change using pre and post treatment values for each antibody. |
| Number of subjects in the transplant desensitization cohort with elimination of non-DSA HLA antibodies at 1:16 dilution | Within 4 weeks of completion of treatment | Descriptive statistical report of number of subjects who had elimination of non-DSA HLA antibodies at 1:16 dilution measured by absolute Mean Fluorescent Intensity (MFI) change and log change using pre and post treatment values for each antibody. |
| Number of subjects in the transplant desensitization cohort with decrease in non-DSA HLA antibodies by one log | Within 4 weeks of completion of treatment | Descriptive statistical report of number of subjects who had a decrease in non-DSA HLA antibodies measured by absolute Mean Fluorescent Intensity (MFI) change and log change using pre and post treatment values for each antibody. |
| Number of subjects in the AMR cohort with improvement or stabilization of lung function as measured by spirometry data | Within 4 weeks of completion of treatment | Pulmonary function (spirometry) data will track forced vital capacity (FVC), forced expiratory volume (FEV1) and forced expiratory flow (FEF) 25-75%. Changes in spirometry will be reported as stabilized, improved or worsened based on comparison of baseline spirometry values obtained prior to treatment plan with serial spirometric testing performed at specified intervals in treatment plan. |
| Number of subjects in the AMR cohort with improvement in oxygenation as measured by Liters/min oxygen at rest | Within 4 weeks of completion of treatment | Gas exchange will be reported as no change, worsening exchange or improving exchange based on comparison of resting oxygen requirements before and following treatment plan. |
Outcome results
None listed